August 14, 2026

Dhanuka Laboratories Limited: Ratings withdrawn

Summary of rating action

Instrument*	Previous rated amount (Rs. crore)	Current rated amount (Rs. crore)	Rating action	Financial sector regulator#
Long-term/Short-term – Fund-based - Cash Credit	91.0	91.0	[ICRA]BBB (Negative)/ [ICRA]A3+; withdrawn	RBI
Short-term - Non-fund based - Others	62.0	62.0	[ICRA]A3+; withdrawn	RBI
Total	**153.0**	**153.0**		

**Instrument details are provided in Annexure I*

#SEBI's grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI.

Rationale

ICRA has withdrawn the ratings assigned to the bank facilities of Dhanuka Laboratories Limited (DLL), at the request of the company and based on the No Objection Certificate received from the lenders and in accordance with ICRA's policy on withdrawal of credit ratings, as DLL has been merged with its subsidiary. However, ICRA does not have information to suggest that the credit risk has changed since the time the rating was last reviewed.

The key rating drivers and their description, liquidity position and rating sensitivities have not been captured as the rated instruments are being withdrawn. The previous detailed rating rationale is available at the following link: Click here.

Analytical approach

Analytical approach	Comments
Applicable rating methodologies	Pharmaceuticals Corporate Credit Rating Methodology Policy on Withdrawal of Credit Ratings
Parent/Group support	The ratings assigned to DLL factored in the likelihood of its associate concern, DAL, extending financial support to it because of the need to protect its reputation from the consequences of a Group entity's distress
Consolidation/Standalone	For arriving at the ratings, ICRA had considered the consolidated financials of DLL. As on March 31, 2026, the company had one subsidiary, which is enlisted in Annexure-II.

About the company

DLL has been merged with its subsidiary Orchid Pharma Limited (OPL). The company was involved in manufacturing and marketing of active pharmaceutical ingredients (APIs) and advanced intermediates of cephalosporin antibiotics since the commencement of its commercial operations in 1998. DLL was promoted by the Dhanuka Group. The Group's flagship company is Dhanuka Agritech Limited (DAL). DLL used to supply cephalosporin products to domestic and overseas non-regulated markets such as Pakistan, Bangladesh, Turkey, South Korea, China etc. through its manufacturing facility in Gurgaon (Haryana). The company diversified its portfolio to non-cephalosporin APIs/intermediates through its Keshwana facility in Rajasthan. Apart from operating in the API segment, DLL was present in formulations segment through Synmedic Laboratories, acquired by DLL in 2013. Synmedic operates a manufacturing facility in Faridabad (Haryana) and mainly sells its products to South East nations such as Vietnam, the Philippines, Cambodia etc. Synmedic has also set up another plant in Rajasthan to increase its manufacturing capacity for the formulations.

OPL, which is a listed entity, was acquired by DPL in March 2020 under the IBC process. OPL also manufactures cephalosporin APIs and formulations and has significant presence in regulated markets such as the US, Europe, Japan etc.

Key financial indicators (audited)

Dhanuka Laboratories Limited (Consolidated)	FY2024	FY2025
Operating income	1376.0	1400.9
PAT	192.1	124.9
OPBDITA/OI	12.2%	11.7%
PAT/OI	14.0%	8.9%
Total outside liabilities/Tangible net worth (times)	0.4	0.3
Total debt/OPBDITA (times)	0.8	0.9
Interest coverage (times)	9.2	12.4

Source: Company, ICRA Research; All ratios as per ICRA's calculations; Amount in Rs. crore; PAT: Profit after tax; OPBDITA: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

	Current ratings (FY2027)			Chronology of rating history for the past 3 years					
				FY2026		FY2025		FY2024	
Instrument	**Type**	**Amount rated (Rs. crore)**	**August 14, 2026**	**Date**	**Rating**	**Date**	**Rating**	**Date**	**Rating**
Fund-based - Cash credit	Long-term/ Short-term	91.0	[ICRA]BBB (Negative)/ [ICRA]A3+; withdrawn	25-Feb - 2026	[ICRA]BBB (Negative)/ [ICRA]A3+	29-Nov - 2024	[ICRA]BBB (Stable)/ [ICRA]A3+	31-Aug-2023	[ICRA]BBB (Stable)/ [ICRA]A3+
Non-fund based - Others	Short-term	62.0	[ICRA]A3+; withdrawn	25-Feb - 2026	[ICRA]A3+	29-Nov - 2024	[ICRA]A3+	31-Aug-2023	[ICRA]A3+

Complexity level of the rated instruments

Instrument	Complexity indicator
Long-term/Short-term - Fund-based - Cash credit	Simple
Short-term - Non-fund based - Others	Simple

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: Click here

Annexure I: Instrument details

ISIN	Instrument name	Date of issuance	Coupon rate	Maturity	Amount rated (Rs. crore)	Current rating and outlook	Financial sector regulator#
NA	**Fund-based – Cash credit**	NA	NA	NA	91.0	[ICRA]BBB (Negative)/ [ICRA]A3+; withdrawn	RBI
NA	**Non-fund based - Others**	NA	NA	NA	62.0	[ICRA]A3+; withdrawn	RBI

Source: Company

#SEBI's grievance redressal/dispute resolution and SEBI investor protection mechanisms such as SCORES and ODR shall not be available for activities and instruments which fall under the regulatory purview of Financial Sector Regulators other than SEBI.

Please click here to view details of lender-wise facilities rated by ICRA

Annexure II: List of entities considered for consolidated analysis

Company name	DLL ownership	Consolidation approach
Orchid Pharma Limited (OPL)	*	Full consolidation

*Source: Company; *DLL used to hold 69.80% equity stake in OPL, however, DLL has been merged with OPL with effect from July 10, 2026*

ANALYST CONTACTS

Jitin Makkar
+91 124 4545 368
jitinm@icraindia.com

Kinjal Kirit Shah
+91 22 6114 3442
kinjal.shah@icraindia.com

Sovanlal Biswas
+91 33 6521 6808
sovanlal.biswas@icraindia.com

Viren Jhunjhunwala
+91 22 6169 3328
viren.jhunjhunwala@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar
+91 22 6114 3406
shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani
Tel: +91 124 4545 860
communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited

Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001
Tel: +91 11 23357940-45

Branches